Archives
Showing 31 - 40 of 52 posts
https://www.coltonconsortium.org/projects/colton-center-for-rna-exploration-in-autoimmune-therapeutics-create/
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
https://www.coltonconsortium.org/publications/transcriptomic-profiling-after-b-cell-depletion-reveals-central-and-peripheral-immune-cell-changes-in-multiple-sclerosis/
https://www.coltonconsortium.org/publications/tolebrutinib-in-nonrelapsing-secondary-progressive-multiple-sclerosis/
https://www.coltonconsortium.org/publications/safety-and-efficacy-of-evobrutinib-in-relapsing-multiple-sclerosis-evolutionrms1-and-evolutionrms2-two-multicentre-randomised-double-blind-active-controlled-phase-3-trials/
https://www.coltonconsortium.org/publications/safety-and-tolerability-of-conversion-to-siponimod-from-other-disease-modifying-therapies-in-patients-with-advancing-forms-of-relapsing-ms-results-from-the-exchange-study/
https://www.coltonconsortium.org/publications/short-and-long-term-effects-of-early-versus-delayed-treatment-with-ocrelizumab-on-cerebellar-volume-loss-in-patients-with-rms-and-ppms/
https://www.coltonconsortium.org/publications/multiple-sclerosis-and-covid-19-interactions-and-unresolved-issues/
https://www.coltonconsortium.org/publications/pediatric-cerebrospinal-fluid-immune-profiling-distinguishes-pediatric-onset-multiple-sclerosis-from-other-pediatric-onset-acute-neurological-disorders/
https://www.coltonconsortium.org/publications/personalized-treatment-decision-algorithms-for-the-clinical-application-of-serum-neurofilament-light-chain-in-multiple-sclerosis-a-modified-delphi-study/
https://www.coltonconsortium.org/publications/diagnostic-performance-of-central-vein-sign-versus-oligoclonal-bands-for-multiple-sclerosis/
